Jim Cramer’s Latest Game Plan: 20 Stocks to Watch

7. Eli Lilly and Company (NYSE:LLY)

Number of Hedge Fund Holders: 100

Regarding Eli Lilly and Company (NYSE:LLY), Cramer previously stated that its peers cannot compete with the amount of firepower it has. This is what he said in the most recent episode:

“Now Wednesday morning, Eli Lilly, one of our best picks for the Charitable Trust… And that’s had quite a run thanks to the GLP-1 weight loss drugs. This morning, Stifel brokerage house put out a note that talks about the impact of these drugs on the food stocks. I think, pretty much everyone else, all the analysts and the people in the food industry, these guys say it’s going to impact the food companies negatively. Well, that means it’s going to impact Lilly positively.”

Eli Lilly (NYSE:LLY) is a leading global pharmaceutical company focused on transforming diabetes care and addressing obesity, along with its serious long-term effects. A significant addition to its portfolio is Zepbound, a novel treatment for obesity that activates specific hormone receptors, representing a fresh approach in the therapeutic landscape. Mounjaro, another key product, is the first approved medication for type 2 diabetes that targets these same receptors, utilizing tirzepatide as its active ingredient.

Recently, Reuters reported that Eli Lilly (NYSE:LLY) plans to launch Mounjaro in Denmark. The pricing for Mounjaro in Denmark is set at DKK 2,200 per month, while competitor Novo Nordisk charges between DKK 1,313 and 2,353 per month for its weight-loss medication Wegovy.

Bloomberg News reported on October 27 that the company expects to introduce Mounjaro in Hong Kong by the end of the year. The Hong Kong government has approved the sale of tirzepatide injections, branded Mounjaro, which will be delivered through a device known as Kwikpen. This approval allows the drug to be marketed for both long-term weight management and the treatment of type 2 diabetes.